Biotechnology Fundraising Reflects Bigger Start-Ups, Fewer IPOs in 2005
This article was originally published in Start Up
Executive Summary
Fundraising among private biotechs has evened out this year, with larger early rounds reflecting the renewed "think-big" strategy of some start ups, and larger late rounds a consequence of less receptive IPO markets.
You may also be interested in...
Biopharma VCs Move to the Middle in 2006
While the venture capital community spent roughly the same in biopharma investments in 2006 as they did in 2005, they put considerably more money into mid-stage companies (Series B and C investments), and slightly less into Series A and mezzanine rounds, than they had in 2005.
Biopharma VCs Move to the Middle in 2006
While the venture capital community spent roughly the same in biopharma investments in 2006 as they did in 2005, they put considerably more money into mid-stage companies (Series B and C investments), and slightly less into Series A and mezzanine rounds, than they had in 2005.
Financing Private Biotechs in 2005: Following the Money
Analyzing VC investments in private companies last year suggests that conventional wisdom is holding: oncology and specialty pharma firms did especially well, pulling in the biggest shares of biopharma private equity in 2005.